In The News

01.09.17
MyoKardia Precision Medicine and HCM
NPR Biotech Nation

01.03.17
Sanofi to Continue Global Cardiomyopathy Research Collaboration with MyoKardia
Reuters

10.31.16
Biotech Snapshot: MyoKardia has a Heart of Gold
Seeking Alpha

08.16.16
Thought Leader’s Corner: Healthcare and Technology
Healthcare Innovation News

07.22.16
Video: Genes and the Heart
CardioSource WorldNews

07.12.16
MyoKardia plans to head into Phase II testing for lead candidate, MYK-461, during second half of 2016
FierceBiotech

05.02.16
MyoKardia Gets Orphan Drug Designation For MYK-461 For Treatment Of oHCM
RTT News

04.30.16
Precision medicine may change management of CVD for cardiologists, patients
Cardiology Today

04.01.16
Creating a Culture of Innovation
PharmaVoice

01.01.16
Precision Medicine
CardioSource WorldNews

11.11.15
Genetic advances opening door to new therapeutic opportunities
American Heart Association

09.30.15
MyoKardia - 2015 Fierce 15
FierceBiotech

05.14.15
SHaRe: advancing the goal of effective treatment for cardiomyopathy
CardioPulse / European Heart Journal

04.07.15
Video: New Hope for Patients with Cardiomyopathies
Sanofi TV

03.24.15
Video: Fixing the Mutations that Drive Cardiomyopathy
CardioSource WorldNews

02.24.15
MyoKardia points its drugs to the heart of life-saving genetics
San Francisco Business Times

02.17.15
HR Exec Reveals In-Demand Jobs at MyoKardia
BioSpace

01.14.15
MyoKardia CEO on approach to fighting heart disease
Fox Business News

11.15.14
Personalized Medicine: Personalized Medicine Gains Momentum
http://www.pharmavoice.com/article/personalized-medicine/

10.23.14
Top 30 Life Science Startups To Watch In The U.S.
BioSpace

09.17.14
MyoKardia, Sanofi Ink $200M+ Deal for Targeted Heart Drugs
Xconomy

09.17.14
Sanofi partners with Myokardia on a "totally new" approach to heart disease
FierceBiotech

07.10.14
New Registry Addresses Genetic Heart Diseases
Empowered Patient Podcast

10.12.12
Startup Targets Genes Tied to Heart Disease
Technology Review

09.20.12
Third Rock bankrolls a new biotech to tackle genetic heart disease
FierceBiotech

09.12.12
Third Rock's MyoKardia Gets $38M for Genetic Forms of Heart Disease
Xconomy

Disclaimer: The above links represent external, third-party information. MyoKardia makes no representation to the accuracy of this information, and does not explicitly endorse materials on those websites.